

# **NHS Kent & Medway Medicines Optimisation Group**

# Recent NICE publications – August 2022

# **FOR INFORMATION**

#### **NICE Publications**

# **NICE clinical guidelines**

# Gout: diagnosis and management published June 2022

This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

#### Multiple sclerosis in adults: management published June 2022

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

# **Depression in adults: treatment and management published June 2022**

This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

#### Urinary tract infection in under 16s: diagnosis and management published July 2022

This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management.

# **Updated NICE Clinical Guidelines**

#### Preterm labour and birth. Updated June 2022

This guideline covers the care of women at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth. In **June 2022**, NICE made new recommendations on the use of repeat courses of maternal corticosteroids.

# Type 2 diabetes in adults: management. Updated June 2022

This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications. In **June 2022**, NICE reviewed the evidence and made new recommendations on periodontitis.

#### Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Updated June 2022

This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes. In **June 2022**, NICE reviewed the evidence and made new recommendations on periodontitis.



#### Type 1 diabetes in adults: diagnosis and management. Updated June 2022

This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications. In **June 2022**, NICE reviewed the evidence and made new recommendations on periodontitis.

#### Pneumonia in adults: diagnosis and management. Updated July 2022

This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment. **July 2022:** NICE reinstated this guideline, which was temporarily withdrawn in May 2020 because of the COVID-19 pandemic, and plan to update it.

#### Melanoma: assessment and management. Updated July 2022

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival. In **July 2022**, NICE made new and updated recommendations on genetic testing, staging, surgery for stages 0 to III melanoma, anticancer treatment for people with stage III and IV melanoma, and follow-up.

# **NICE COVID Rapid Guidelines**

### No new NICE Rapid Guidelines

### **Updated NICE COVID Rapid Guidelines**

# COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200] Updated June 2022

This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. On **22 June 2022**, NICE updated the advice on plasma exchange with fresh frozen plasma in people at high risk of a poor prognosis to recommend it is considered earlier in the care pathway.

#### COVID-19 rapid guideline: managing COVID-19 [NG191] Updated July 2022

This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. **14 July 2022:** NICE updated recommendations on using remdesivir in hospital, and added a recommendation on vitamin D for treating COVID-19

# COVID-19 rapid guideline: vitamin D [NG187] Updated July 2022

This guideline covers vitamin D use in the context of COVID-19. It is for adults, young people and children in hospitals and community settings. Vitamin D is important for bone and muscle health. It may also have a role in the body's immune response to respiratory viruses. On **14 July 2022**, NICE removed the content on vitamin D for treating COVID-19 and added information on this into NICE's COVID-19 rapid guideline on managing COVID-19.

#### COVID-19 rapid guideline: haematopoietic stem cell transplantation [NG164] Updated July 2022

The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection. On **20 July 2022**, NICE updated the guideline to reflect changes to best practice and service organisation, which have been adapted over time thorough out the pandemic.

Developed by: NHS Kent & Medway Medicines Optimisation Team

Final Version:



#### **NICE Quality Standards**

No new NICE Quality Standards

# **Updated NICE Quality Standards**

#### Urinary tract infection in children and young people. Updated July 2022

This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement. In **July 2022**, changes were made to align this quality standard with the updated NICE guideline on urinary tract infections in under 16s.

# Fever in under 5s. Updated July 2022

This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement. In **July 2022**, changes were made to align this quality standard with the updated NICE guideline on urinary tract infection in under 16s.

# Skin cancer. Updated July 2022

This quality standard covers preventing, assessing, diagnosing and managing skin cancer (malignant melanoma and non-melanoma). It describes high-quality care in priority areas for improvement. In **July 2022**, changes were made to align this quality standard with the updated NICE guideline on melanoma.



Developed by: NHS Kent & Medway Medicines Optimisation Team

Final Version: